Inactive Instrument

Neuralstem, Inc. Share Price NYSE

US64127R3021

End-of-day quote NYSE
- ^USD	-

11/08	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
23/07	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT

Latest news : Neuralstem, Inc.

11/08	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
23/07	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
30/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Small Cap Comp Growth Benchmark	CI
30/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2500 Growth Benchmark	CI
30/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Index	CI
30/06	Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis	CI
29/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Value Benchmark	CI
29/06	Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial	DJ
29/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Value Benchmark Index	CI
29/06	Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study	MT
29/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Growth Benchmark Index	CI
29/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Growth Benchmark	CI
29/06	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 3000E Growth Benchmark	CI

More news

Analysts' recommendations: Neuralstem, Inc.

23/07	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
26/03	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
25/02	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
09/01	B. Riley Initiates Palisade Bio at Buy With $7 Price Target	MT
17/23/17	Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	MT

More recommendations

Press Releases: Neuralstem, Inc.

11/08	Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development	AQ
10/07	Palisade Bio to Participate in the Leerink Partners Therapeutics Forum	AQ
29/06	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis	AQ
11/06	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors	AQ
10/06	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium	AQ

More press releases

News in other languages: Neuralstem, Inc.

30/24/30	MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen
29/24/29	LATE BRIEFING - Unternehmen und Märkte
29/24/29	MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung
29/24/29	MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche
29/24/29	MÄRKTE USA/Wall Street wenig verändert erwartet

More news

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Employees

Sector

More about the company

Market Cap	37Cr 32Cr 30Cr 28Cr 52Cr 3.58TCr 53Cr 355.74Cr 139.4Cr 1.79TCr 140.67Cr 137.62Cr 5.97TCr	P/E 2026 *	-9.56x	P/E 2027 *	-7.78x
Enterprise Value	28Cr 24Cr 22Cr 20Cr 38Cr 2.65TCr 39Cr 262.98Cr 103.05Cr 1.33TCr 103.99Cr 101.74Cr 4.41TCr	EV / Sales 2026 *	776x	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

	2026 *	2027 *
Net sales	4L 3L 3L 3L 5L 3.41Cr 5L 33.91L 13.29L 1.71Cr 13.41L 13.12L 5.69Cr	-
Net income	-4.79Cr -4.13Cr -3.88Cr -3.53Cr -6.64Cr -457.63Cr -6.73Cr -45Cr -18Cr -229.27Cr -18Cr -18Cr -762.66Cr	-6.3Cr -5.44Cr -5.11Cr -4.65Cr -8.75Cr -602.82Cr -8.87Cr -60Cr -23Cr -302.01Cr -24Cr -23Cr -1TCr
Net Debt	-9.77Cr -8.43Cr -7.91Cr -7.21Cr -14Cr -934.14Cr -14Cr -93Cr -36Cr -468Cr -37Cr -36Cr -1.56TCr	-33Cr -29Cr -27Cr -25Cr -46Cr -3.2TCr -47Cr -317.78Cr -124.53Cr -1.6TCr -125.66Cr -122.94Cr -5.33TCr

Neuralstem, Inc. Share Price NYSE

Stocks

US64127R3021

Valuation: Neuralstem, Inc.

Latest news : Neuralstem, Inc.

Analysts' recommendations: Neuralstem, Inc.

Press Releases: Neuralstem, Inc.

News in other languages: Neuralstem, Inc.

Financials

Company Profile